340B Insider – July 2018
Welcome to the July edition of RxStrategies’ 340B Insider, a concise communication to provide a quick highlight of updates from RxStrategies’ view. UPDATES FROM THE 340B COALITION SUMMER CONFERENCE It was great to connect with so many of our clients and industry leaders during the 340B Coalition Summer Conference in Washington D.C. In addition to being a…
Clinical Insights: February 13, 2018
Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. New Drug Approval Biktarvy® (bictegravir, emtricitabine and tenofovir alafenamide) – February 7, 2018 – Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved Biktarvy®…
Clinical Insights: February 5, 2018
Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. New Drug Approval FirvanqTM (vancomycin hydrochloride) – January 29, 2018 – CutisPharma announced that the U.S. Food and Drug Administration (FDA) has approved Firvanq™ (vancomycin hydrochloride) for oral solution, for the…
Clinical Insights: January 22, 2018
Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. New Drug Approval BalcoltraTM (levonorgestrel and ethinyl estradiol and ferrous bisglycinate) – January 19, 2018 – Avion Pharmaceuticals, LLC, received approval of its new drug application (NDA) for the oral contraceptive…
Clinical Insights: January 15, 2018
Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. New Drug Approval No new updates. New Formulation Approval No new updates. New Indication Approval Lynparza® (olaparib) – January 12, 2018 – The Food and Drug Administration…
Clinical Insights: August 18, 2017
Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. New Drug Approval Besponsa® (inotuzumab ozogamicin) – August 17, 2017 – The U.S. Food and Drug Administration approved Besponsa® (inotuzumab ozogamicin) for the treatment of adults with relapsed or…
Clinical Insights: August 11, 2017
Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. New Drug Approval CaroSpir® (spironolactone) – August 7, 2017 – CMP Pharma announced that the U.S. Food and Drug Administration (FDA) has granted final approval of the company’s New…